Biotechnology · Waltham, Massachusetts, United States
n/a
Smart-Money SignalNeutral · 48/100— Insiders are net sellers over 90 days (-$7K, 2 sales vs 1 buy)
Net Income-$200.7M
EPS$10.86
Price Performance
Historical data including institutional events
Company Profile
S
Sherwin Sattarzadeh
CEO & Executive Director
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The companyâs lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Founded
- 2011
- Employees
- 5
- Headquarters
- Waltham, Massachusetts, United States
- Website
- www.damoratx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...